MARKET

PLXP

PLXP

PLx Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.56
-0.22
-3.81%
Opening 13:27 01/22 EST
OPEN
5.80
PREV CLOSE
5.78
HIGH
5.93
LOW
5.50
VOLUME
26.18K
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
1.800
MARKET CAP
77.35M
P/E (TTM)
-4.7135
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
8-K: PLx Pharma Inc.
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/12 05:39
The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 22)
Benzinga · 12/23/2020 13:29
The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)
Benzinga · 12/22/2020 12:45
Is PLx Pharma Inc. (PLXP) A Good Stock To Buy?
Insider Monkey · 11/27/2020 18:23
Is PLx Pharma Inc. (PLXP) A Good Stock To Buy?
Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are indust...
Insider Monkey · 11/27/2020 18:23
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 11/24/2020 13:12
Lexicon Pharmaceuticals, Zomedica Pharmaceuticals leads healthcare gainers; Brainstorm Cell Therapeutics, GoodRx Holdings among losers
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) -19%, iBio (IBIO) -18%, Co-Diagnostics (CODX) -17%, Alterity Therapeutics (ATHE) -16%.
Seekingalpha · 11/17/2020 16:06
The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 16)
Benzinga · 11/17/2020 13:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PLXP. Analyze the recent business situations of PLx Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PLXP stock price target is 9.00 with a high estimate of 9.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 2.06M
% Owned: 14.77%
Shares Outstanding: 13.91M
TypeInstitutionsShares
Increased
4
9.74K
New
5
33.26K
Decreased
2
1.23K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+0.73%
Key Executives
Chief Financial Officer
Rita O'Connor
Chief Financial Officer
Rita O Connor
Chief Accounting Officer/Treasurer
Robert Shawah
Vice President/Director of Sales
Steven Valentino
Vice President
Tom Long
Director
Gary Balkema
Director
Tony Bartsh
Director
Anthony Bartsh
Director
Kirk Calhoun
Director
Robert Casale
Director
Natasha Giordano
Director
John Hadden
Director
Michael Valentino
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PLXP
PLx Pharma Inc. is a late-stage specialty pharmaceutical company. It is focusing on developing clinically-validated and patent-protected PLxGuard delivery system. Its lead product, Vazalore 325 mg, which is a formulation of aspirin using the PLxGuard delivery system intended to provide antiplatelet for cardiovascular disease prevention as compared to the current standard of care, enteric-coated aspirin, and significantly reduce gastric side effects. The Company has also developed Vazalore 81 mg, a lower-dose companion product for Vazalore 325 mg. The PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. Its product pipeline also includes other oral NSAIDs using the PLxGuard delivery system that may be developed, including a clinical-stage, GI-safer ibuprofen, PL1200 Ibuprofen 200 mg, for pain and inflammation.
More

Webull offers kinds of PLx Pharma Inc stock information, including NASDAQ:PLXP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLXP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PLXP stock methods without spending real money on the virtual paper trading platform.